Journal Watch · Frontiers in Immunology · 2026

Anti-trapping scaffold protein: significance in cancer cell innate immune signaling and opportunities for immunotherapy.

This may represent a therapeutic vulnerability that warrants further evaluation in gastric cancer, particularly in studies combining DNA damage response (DDR) inhibition with immunotherapy.

Kidane DFrontiers in Immunology3 min readPharma relevance 50/100

DOI: 10.3389/fimmu.2026.1905777PMID: 42819196Study type: research study

TL;DR

This may represent a therapeutic vulnerability that warrants further evaluation in gastric cancer, particularly in studies combining DNA damage response (DDR) inhibition with immunotherapy.

Key findings

  • Recently, Shahi et al. demonstrated that XRCC1 deficiency combined with pharmacological inhibition of Ataxia-Telangiectasia Mutated (ATM) induces mitotic failure, resulting in the accumulation of cytosolic DNA and activation of cancer cell-intrinsic innate immune signaling.
  • Notably, this response was associated with increased PD-L1 expression, which may contribute to adaptive immune resistance.
  • Collectively, these findings suggest that XRCC1 deficiency can promote cancer-cell-intrinsic molecular features associated with innate immune activation.
  • This may represent a therapeutic vulnerability that warrants further evaluation in gastric cancer, particularly in studies combining DNA damage response (DDR) inhibition with immunotherapy.

Numbers at a glance (from the abstract)

30%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Preclinical studies have shown that XRCC1 deficiency delays SSB rejoining, induces mutations, and results in elevated levels of sister chromatid exchanges, a hallmark of genomic instability. XRCC1 deficiency results in hypersensitivity to ionizing radiation and chemotherapeutics. Analyses of the Cancer Genome Atlas (TCGA) datasets have revealed that approximately 30% of tumors exhibit low XRCC1 expression.

Full abstract (original)

Background: X-ray repair cross-complementing protein 1 (XRCC1) is a scaffold protein that functions as a molecular hub, serving as a platform for the recruitment and interaction of multiple DNA repair proteins to coordinate and facilitate multistep DNA repair processes. Furthermore, it acts as an antitrapping protein, ensuring the timely release of DNA repair proteins to prevent genotoxicity. XRCC1 participates in single-strand break repair (SSBR) pathways and has also been implicated in other DNA repair pathways.

What they did: Preclinical studies have shown that XRCC1 deficiency delays SSB rejoining, induces mutations, and results in elevated levels of sister chromatid exchanges, a hallmark of genomic instability. XRCC1 deficiency results in hypersensitivity to ionizing radiation and chemotherapeutics. Analyses of the Cancer Genome Atlas (TCGA) datasets have revealed that approximately 30% of tumors exhibit low XRCC1 expression.

Results & conclusions: Recently, Shahi et al. demonstrated that XRCC1 deficiency combined with pharmacological inhibition of Ataxia-Telangiectasia Mutated (ATM) induces mitotic failure, resulting in the accumulation of cytosolic DNA and activation of cancer cell-intrinsic innate immune signaling. Notably, this response was associated with increased PD-L1 expression, which may contribute to adaptive immune resistance. Collectively, these findings suggest that XRCC1 deficiency can promote cancer-cell-intrinsic molecular features associated with innate immune activation. This may represent a therapeutic vulnerability that warrants further evaluation in gastric cancer, particularly in studies combining DNA damage response (DDR) inhibition with immunotherapy.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1905777 · PubMed 42819196.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

This may represent a therapeutic vulnerability that warrants further evaluation in gastric cancer, particularly in studies combining DNA damage response (DDR) inhibition with immunotherapy.

What type of study is this?

It is a research study, published in Frontiers in Immunology in 2026. Preclinical studies have shown that XRCC1 deficiency delays SSB rejoining, induces mutations, and results in elevated levels of sister chromatid exchanges, a hallmark of genomic instability.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1905777. PubMed ID: 42819196. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Kidane D. Anti-trapping scaffold protein: significance in cancer cell innate immune signaling and opportunities for immunotherapy.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1905777.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/anti-trapping-scaffold-protein-significance-in-cancer-cell-innate-immune-905777/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides